Skip to main content
main-content

Medication and diabetic complications

Interactive patient case study

Hypoglycemia and technology

Hypoglycemia and technology

This 15-minute case presents the identification of problematic hypoglycemia and the appropriate use and monitoring of different technologies in the context of reducing the occurrence and risk of hypoglycemia.

Get more on: Hypoglycemia | Devices and technology | Pediatric diabetes

medwireNews editor's pick

No fracture risk found with canagliflozin in real-world data

Cervical hip (femoral neck) fracture

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

Expert opinion editorial

Diabetes and obstructive sleep apnea syndrome: Double trouble

Sleep apnea (symbolic image with model)

Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition [read more].

Get more on: Sleep disorders | Obesity | Type 2 diabetes complications

medwireNews editor's pick

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

New Content Item

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

medwireNews editor's pick

Insulin manipulation strongly linked to psychiatric comorbidity

Insulin pen

Insulin manipulation, the practice of deliberately under- or overdosing insulin, is strongly associated with psychiatric comorbidity in children and young adults with type 1 diabetes, Austrian research shows.

medwireNews editor's pick

EASE: Add-on empagliflozin improves glycemic control in type 1 diabetes

Pills

The addition of empagliflozin to insulin therapy reduces glycated hemoglobin levels in patients with type 1 diabetes, indicate findings from the phase III EASE-2 and 3 trials.

View from the clinic

Regaining sexual health in diabetes: Start with open communication

Worried senior man sits on bed (symbolic image with models)

Advisory Board member Clipper Young recounts an experience of starting a patient with erectile dysfunction on the path to appropriate treatment for him and his diabetes [read more].

Get more on: Diabetic complications | Psychosocial care | View from the clinic

Journal article

Prevention and management of severe hypoglycemia and hypoglycemia unawareness: Incorporating sensor technology

Woman with flash glucose monitor (symbolic image with model)

In this paper, the authors report on the current scientific evidence on the effectiveness of continuous glucose monitoring sensor technology in the prevention of severe hypoglycemia and hypoglycemia unawareness [read more].
Lucidi P et al. Curr Diab Rep 2018; 18: 83. doi: 10.1007/s11892-018-1065-6

Get more on:  Devices and technology | Diabetic complications | Type 1 diabetes

Case study

Acute illness while on a SGLT2 inhibitor and ketogenic diet

AdobeStock_88855376

Advisory Board member Theresa Smyth tackles an emergency case involving a type 2 diabetes patient on a new diet and treated with empagliflozin. What went wrong and how should he be managed? [Read more].

Get more on: SGLT2 inhibitors | Diet and nutritional management | Case studies

medwireNews editor's pick

Neutral cardiovascular safety for lorcaserin in CAMELLIA-TIMI 61

Heartbeat

The weight-loss medication lorcaserin neither increases nor reduces cardiovascular risk, report the CAMELLIA–TIMI 61 investigators.

medwireNews

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

11-14-2018 | SGLT2 inhibitors | News

Registry study supports SGLT2 inhibitor amputation risk

A registry study in The BMJ finds a small but significant increased risk for amputations in patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors.

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

10-26-2018 | PCSK9 inhibitors | Review | Article

Inhibiting PCSK9: Biology beyond LDL control

Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5

10-08-2018 | Dapagliflozin | Article

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

Soga F et al. Cardiovasc Diabetol 2018; 17: 132. doi: 10.1186/s12933-018-0775-z

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

image credits